bioAffinity Technologies (BIAF) Registration filing summary

Company overview and business model

• Develops noninvasive diagnostic tests for early-stage lung cancer and other lung diseases using flow cytometry and AI-driven analysis.

• First commercial product, CyPath® Lung, targets early detection of lung cancer with high sensitivity and specificity.

• Expanding diagnostic pipeline to asthma and COPD companion diagnostics and researching novel cancer therapeutics.

• Recent distribution agreement with AvMEDICAL aims to expand reach into government healthcare markets.

• Relocated research operations from university-leased space to private labs in 2026.

Financial performance and metrics

• Net proceeds from August 2026 private placement were approximately $3.6 million after fees and expenses.

• Auditors included a going concern explanatory paragraph in the 2025 and 2024 financial statements.

Use of proceeds and capital allocation

• Proceeds from warrant exercises, if any, could total up to $8.2 million; actual timing and amount are uncertain.

• Net proceeds from the private placement are intended for working capital and general corporate purposes.